Business Segments · Selling, informational and administrative expenses
Business Segments — Selling, informational and administrative expenses
Pfizer Business Segments — Selling, informational and administrative expenses decreased by 2.5% to $2.13B in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toSG&A
How to read this metric
Lower expenses relative to revenue suggest better operating leverage and sales force efficiency.
Detailed definition
Operating expenses related to marketing, sales force support, medical information dissemination, and general administrat...
Peer comparison
Commonly referred to as SG&A, this is a standard benchmark for operational overhead in the industry.
Metric ID:
pfe_segment_biopharma_selling_informational_and_administrative_expensesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.19B | $2.13B |
| QoQ Change | — | -2.5% |
| YoY Change | — | -2.5% |
Range$2.13B – $2.19B
Avg YoY Growth-2.5%
Median YoY Growth-2.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — selling, informational and administrative expenses?
- Pfizer (PFE) reported business segments — selling, informational and administrative expenses of $2.13B in Q1 2026.
- What does business segments — selling, informational and administrative expenses mean?
- The costs of marketing, selling, and managing the biopharma segment's operations.